In vivo, NLX-101 exhibits pro-motor influence in rats with dopaminergic lesions, potent antidepressant-like properties (Assie et al., 2010), pro-cognitive activity (Depoortere et al., 2010); and, in MeCP2 mice, reverses respiratory disturbance (Levitt et al., 2013), properties that would be desirable in a pharmacotherapy strategy for Rett syndrome. Here, MECP2 is linked to atypical Rett syndrome.